A Second Pivotal Study is evaluating Zepsyre ( Lurbinectedin ) in combination with Doxorubicin in patients with Small Cell Lung Cancer ( SCLC ).
A Phase III in BRCA2-Mutated Breast Cancer is Planned, and Pivotal studies in Endometrial Cancer have been flagged following a 44% response rate in Phase I.
*********************
Del último informe de Edison ... Eliminaramos Aplidin ... Nos Quedaría un Precio Objetivo de 7,38 euros :
